Trilostane therapy for hyperadrenocorticism in three dogs with adrenocortical metastasis.

IN dogs, more than half of the adrenal tumours responsible for hyperadrenocorticism are malignant ([Reusch and Feldman 1991][1]). They can be metastasised by the time of diagnosis or after surgical resection. Medical management is therefore required to control the clinical signs. Trilostane is an